Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Next Previous
Trial Profile

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cemiplimab (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Olvimulogene nanivacirepvec (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms VIRO-25
  • Sponsors Genelux Corporation

Most Recent Events

  • 05 Jan 2026 According to a Genelux Corporation media release,Additional interim (updated dose-finding) data readouts are expected throughout 2026.
  • 05 Jan 2026 Interim results presented in the Genelux Corporation media release.
  • 05 Nov 2025 According to a Genelux Corporation media release, interim data expected in fourth quarter of 2025 and throughout 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top